The NeurologyLive® headache and migraine clinical focus page offers information, podcasts, videos, and news and interviews with physicians related to the care of patients with headache disorders such as chronic and episodic migraine, cluster headache, tension-type headache, and more. The page includes updates on the latest FDA actions, clinical guidelines, and study and clinical trial findings.
August 16th 2025
A recent study reassured that triptans may be safe for migraine treatment, emphasizing the need for individualized assessments of cardiovascular risks.
How APPs and Organizations Can Address the Neurologist Shortage: Jennifer Majersik, MD, MS
September 16th 2021The director of the division of vascular neurology at the University of Utah discussed ongoing efforts from the AAN, as well as the potential to integrate advanced practice providers into neurology teams.
Addressing the Neurologist Shortage and Increased Need for Neurologic Care
September 10th 2021Jennifer Majersik, MD, MS, division chief of vascular neurology at the University of Utah, discussed contributing factors to the neurologist shortage, as well as ongoing efforts to increase interest in the field.
NeuroVoices: Paul G. Mathew, MD, on Educating Clinical Community on Nerve Block Surgery Benefits
September 8th 2021The assistant professor of neurology at Harvard Medical School provided insight on how to improve care for posttraumatic headache, as well as limitations and benefits to nerve block surgeries.
Caring for Transgender and Gender-Diverse Patients With Migraine: Jennifer Hranilovich, MD
September 5th 2021Discussing the key takeaways for clinicians when it comes to treating this patient population, the assistant professor of pediatrics and neurology at the University of Colorado School of Medicine emphasized the need to improve communication.
Importance of Headache Research for Transgender and Gender-Diverse Patients
August 29th 2021Jennifer Hranilovich, MD, assistant professor of pediatrics and neurology at the University of Colorado School of Medicine, discussed a recent narrative review that evaluated research on headache in transgender and gender-diverse patients.
ADVANCE Study Results Demonstrate Atogepant’s Potential for Migraine Prevention
August 24th 2021For the primary end point, the 3 dose options atogepant (AbbVie) were associated with a reduction ranging from 3.9 to 4.2 days in the mean number of headache days per month for those with episodic migraine.